Trust helps demonstrate effectiveness of a Covid vaccine
21 October 2021
Chelsea and Westminster Hospital NHS Foundation Trust was part of a study which showed the Valneva Covid-19 vaccine produced a high antibody response to the disease.
Chelsea and Westminster Hospital NHS Foundation Trust was part of a study which showed the Valneva Covid-19 vaccine produced a high antibody response to the disease. The trial compared this vaccine with that produced by AstraZeneca. Further trials will establish how effective the vaccine is at preventing disease.
Valneva uses a more traditional vaccine technology, using a harmless broken version of the virus which causes Covid-19. It is not possible to catch the disease from the vaccine.
Every trial relies on volunteers from the general public. 122 participants were recruited to the trial and full use was made of the Trust’s Clinical Research Facility (CRF) which is a Covid-safe separate facility to the main hospital, and networked with the other NIHR CRFs in North West London.
Site Principal Investigator Professor Marta Boffito said, 'Our thanks to the volunteers who came forward so quickly and helped us assess this vaccine. Covid-19 remains a very significant health issue across the world and vaccine development is important to improve access and choice.’
We are pleased to be one of 20 NIHR sites and a report on the study is below.